Gln-TAG Program
Gln-TAG (Glutamine to TAG) Liver Stop Codon Disease (e.g., Phenylketonuria, Organic Acidemias, Urea Cycle Disorders)
DiscoveryTarget identified
Key Facts
Indication
Gln-TAG (Glutamine to TAG) Liver Stop Codon Disease (e.g., Phenylketonuria, Organic Acidemias, Urea Cycle Disorders)
Phase
Discovery
Status
Target identified
Company
About Alltrna
Alltrna, a Flagship Pioneering company, is unlocking the therapeutic potential of transfer RNA (tRNA) to create a new paradigm in genetic medicine. Its platform aims to treat thousands of diseases with a single, universal tRNA medicine by correcting shared premature termination codon (PTC) mutations. The company has demonstrated preclinical proof-of-concept for its first development candidate, AP003, and is building a robust pipeline for liver and other stop codon diseases. Backed by significant venture capital, Alltrna is led by an experienced team focused on translating its novel platform into transformative therapies.
View full company profile